Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ)
CNY 20.53
(3.53%)
CNY 20.53
(3.53%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.32 Billion CNY | -5.11% |
| 2022 | 2.45 Billion CNY | 44.34% |
| 2021 | 1.69 Billion CNY | 30.73% |
| 2020 | 1.29 Billion CNY | 58.92% |
| 2019 | 817.55 Million CNY | -14.26% |
| 2018 | 953.49 Million CNY | 30.26% |
| 2017 | 732 Million CNY | 35.4% |
| 2016 | 540.61 Million CNY | -5.15% |
| 2015 | 570 Million CNY | 14.0% |
| 2014 | 500 Million CNY | 89.54% |
| 2013 | 263.8 Million CNY | 17.51% |
| 2012 | 224.5 Million CNY | 41.64% |
| 2011 | 158.5 Million CNY | -9.05% |
| 2010 | 174.28 Million CNY | 106.98% |
| 2009 | 84.2 Million CNY | 11.08% |
| 2008 | 75.8 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 2.03 Billion CNY | -12.47% |
| 2024 Q2 | 2.58 Billion CNY | 26.78% |
| 2024 Q3 | 1.64 Billion CNY | -36.36% |
| 2023 Q4 | 2.32 Billion CNY | -5.27% |
| 2023 Q3 | 2.45 Billion CNY | -6.64% |
| 2023 FY | 2.32 Billion CNY | -5.11% |
| 2023 Q2 | 2.63 Billion CNY | 4.39% |
| 2023 Q1 | 2.51 Billion CNY | 2.78% |
| 2022 Q3 | 2.19 Billion CNY | -8.78% |
| 2022 Q2 | 2.4 Billion CNY | 15.67% |
| 2022 FY | 2.45 Billion CNY | 44.34% |
| 2022 Q1 | 2.07 Billion CNY | 22.33% |
| 2022 Q4 | 2.45 Billion CNY | 11.83% |
| 2021 Q1 | 1.23 Billion CNY | -5.22% |
| 2021 FY | 1.69 Billion CNY | 30.73% |
| 2021 Q2 | 1.12 Billion CNY | -8.4% |
| 2021 Q4 | 1.69 Billion CNY | -0.76% |
| 2021 Q3 | 1.71 Billion CNY | 51.74% |
| 2020 FY | 1.29 Billion CNY | 58.92% |
| 2020 Q1 | 967.96 Million CNY | 18.4% |
| 2020 Q2 | 1.23 Billion CNY | 27.88% |
| 2020 Q3 | 1.51 Billion CNY | 22.66% |
| 2020 Q4 | 1.29 Billion CNY | -14.42% |
| 2019 Q1 | 897 Million CNY | -5.93% |
| 2019 FY | 817.55 Million CNY | -14.26% |
| 2019 Q2 | 926.64 Million CNY | 3.31% |
| 2019 Q3 | 1.04 Billion CNY | 12.25% |
| 2019 Q4 | 817.55 Million CNY | -21.4% |
| 2018 Q2 | 1.05 Billion CNY | 27.37% |
| 2018 FY | 953.49 Million CNY | 30.26% |
| 2018 Q4 | 953.49 Million CNY | 13.02% |
| 2018 Q3 | 843.67 Million CNY | -19.71% |
| 2018 Q1 | 825 Million CNY | 12.7% |
| 2017 Q4 | 732 Million CNY | 6.86% |
| 2017 FY | 732 Million CNY | 35.4% |
| 2017 Q3 | 685 Million CNY | 35.48% |
| 2017 Q2 | 505.61 Million CNY | -15.39% |
| 2017 Q1 | 597.61 Million CNY | 10.54% |
| 2016 Q4 | 540.61 Million CNY | 9.66% |
| 2016 Q2 | 530 Million CNY | -10.17% |
| 2016 Q1 | 590 Million CNY | 3.51% |
| 2016 FY | 540.61 Million CNY | -5.15% |
| 2016 Q3 | 493 Million CNY | -6.98% |
| 2015 Q3 | 541.81 Million CNY | -6.32% |
| 2015 Q2 | 578.34 Million CNY | 20.49% |
| 2015 Q1 | 480 Million CNY | -4.0% |
| 2015 FY | 570 Million CNY | 14.0% |
| 2015 Q4 | 570 Million CNY | 5.2% |
| 2014 Q4 | 500 Million CNY | 0.6% |
| 2014 FY | 500 Million CNY | 89.54% |
| 2014 Q2 | 516.03 Million CNY | 60.76% |
| 2014 Q1 | 321 Million CNY | 21.68% |
| 2014 Q3 | 497 Million CNY | -3.69% |
| 2013 Q2 | 296.2 Million CNY | 11.98% |
| 2013 Q4 | 263.8 Million CNY | 1.46% |
| 2013 Q3 | 260 Million CNY | -12.22% |
| 2013 FY | 263.8 Million CNY | 17.51% |
| 2013 Q1 | 264.5 Million CNY | 17.82% |
| 2012 Q1 | 155 Million CNY | -2.21% |
| 2012 FY | 224.5 Million CNY | 41.64% |
| 2012 Q2 | 151 Million CNY | -2.58% |
| 2012 Q3 | 245.5 Million CNY | 62.58% |
| 2012 Q4 | 224.5 Million CNY | -8.55% |
| 2011 Q3 | 190 Million CNY | -22.86% |
| 2011 Q2 | 246.29 Million CNY | 0.0% |
| 2011 Q4 | 158.5 Million CNY | -16.58% |
| 2011 FY | 158.5 Million CNY | -9.05% |
| 2010 FY | 174.28 Million CNY | 106.98% |
| 2010 Q4 | 174.28 Million CNY | 0.0% |
| 2009 FY | 84.2 Million CNY | 11.08% |
| 2008 FY | 75.8 Million CNY | 0.0% |